Navigation Links
Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
Date:8/22/2011

SEATTLE, Aug. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use ("CHMP") in regards to CTI's Marketing Authorization Application for pixantrone (the "MAA") to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). With this submission, CTI expects to receive a CHMP opinion regarding approvability of pixantrone during the first quarter of 2012.

"We have now submitted answers to the CHMP list of questions moving pixantrone a step closer to potential approval," said James A. Bianco, CEO of CTI. "Following an encouraging meeting with the EMA earlier this year and based on recommendations from the rapporteurs, we requested and received an extension to answer all the EMA's questions in the Day 120 letter. We believe we have been able to provide quality responses to each of the questions posed and we expect this positions us to receive an opinion by the early next year.  If the opinion is positive, we expect that the commercial launch of pixantrone in Europe could occur as early as the first half of 2012."

In the United States, CTI expects to resubmit its New Drug Application for pixantrone (the "NDA") to the U.S. Food and Drug Administration (the "FDA") during the fourth quarter of 2011 and the FDA has indicated the NDA would receive a six month review resulting in a decision on approval of the NDA by the FDA in the United States as early as April 2012.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that CTI may not receive an opinion regarding approvability of pixantrone from the CHMP in the first  quarter of 2012, that the CHMP may request additional information from CTI regarding pixantrone, that CTI may not receive a positive opinion from the CHMP, that CTI may not be able to commence commercialization of pixantrone in the first half 2012, that CTI may not resubmit the NDA for approval to the FDA during the fourth quarter of 2011, that the FDA's review of the NDA may take longer than six months, that the FDA may not approve the NDA as early as April 2012 or at all, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com

Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
2. Echo Therapeutics Announces Second Quarter 2011 Financial Results
3. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
4. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
5. Echo Therapeutics Unveils Symphony tCGM Demonstration Video
6. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
7. Echo Therapeutics Announces Multiple Patents and Trademark Grants
8. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
9. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
10. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
11. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):